--------------------------------
| OMB APPROVAL |
| |
| OMB Number: 3235-0145 |
| |
| Expires: February 28, 2009 |
| Estimated average burden |
| hours per response 14.5 |
--------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
GENTIUM SpA
--------------------------------------------------------------------------------
(Name of Issuer)
AMERICAN DEPOSITARY SHARES, EACH REPRESENTING ONE ORDINARY SHARE
--------------------------------------------------------------------------------
(Title of Class of Securities)
37250B14
--------------------------------------------------------------------------------
(CUSIP Number)
DR. JEFFREY R. JAY, MD
GREAT POINT PARTNERS, LLC
165 MASON STREET, 3RD FLOOR
GREENWICH, CT 06830.
(203) 971-3300
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
JUNE 15, 2007
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box.|_|
NOTE: Schedule filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See ss.240.13d-7 for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
PERSONS WHO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE
NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL
NUMBER.
---------------------
CUSIP No. 37250B14
---------------------
================================================================================
1 Names of Reporting Persons.
Great Point Partners, LLC
I.R.S. Identification Nos. of above persons (entities only).
37-1475292
--------------------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3 SEC Use Only
--------------------------------------------------------------------------------
4 Source of Funds (See Instructions) AF
--------------------------------------------------------------------------------
5 Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e) |_|
--------------------------------------------------------------------------------
6 Citizenship or Place of Organization Delaware
--------------------------------------------------------------------------------
Number of Shares 7 Sole Voting Power -0-
----- ----------------------------------------
Beneficially Owned by 8 Shared Voting Power 425,532
----- ----------------------------------------
Each Reporting Person With 9 Sole Dispositive Power -0-
----- ----------------------------------------
10 Shared Dispositive Power 425,532
--------------------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned by Each Reporting Person 425,532
--------------------------------------------------------------------------------
12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions) |_|
--------------------------------------------------------------------------------
13 Percent of Class Represented by Amount in Row (11) 2.92%
--------------------------------------------------------------------------------
14 Type of Reporting Person (See Instructions)
OO
================================================================================
2
---------------------
CUSIP No. 37250B14
---------------------
================================================================================
1 Names of Reporting Persons.
Dr. Jeffrey R. Jay, M.D.
I.R.S. Identification Nos. of above persons (entities only).
--------------------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3 SEC Use Only
--------------------------------------------------------------------------------
4 Source of Funds (See Instructions) AF
--------------------------------------------------------------------------------
5 Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e) |_|
--------------------------------------------------------------------------------
6 Citizenship or Place of Organization United States
--------------------------------------------------------------------------------
Number of Shares 7 Sole Voting Power -0-
----- ----------------------------------------
Beneficially Owned by 8 Shared Voting Power 425,532
----- ----------------------------------------
Each Reporting Person With 9 Sole Dispositive Power -0-
----- ----------------------------------------
10 Shared Dispositive Power 425,532
--------------------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned by Each Reporting Person 425,532
--------------------------------------------------------------------------------
12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions) |_|
--------------------------------------------------------------------------------
13 Percent of Class Represented by Amount in Row (11) 2.92%
--------------------------------------------------------------------------------
14 Type of Reporting Person (See Instructions)
IN
================================================================================
3
---------------------
CUSIP No. 37250B14
---------------------
================================================================================
1 Names of Reporting Persons.
Biomedical Value Fund, L.P.
I.R.S. Identification Nos. of above persons (entities only).
20-0308288
--------------------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3 SEC Use Only
--------------------------------------------------------------------------------
4 Source of Funds (See Instructions) PF
--------------------------------------------------------------------------------
5 Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e) |_|
--------------------------------------------------------------------------------
6 Citizenship or Place of Organization Delaware
--------------------------------------------------------------------------------
Number of Shares 7 Sole Voting Power -0-
----- ----------------------------------------
Beneficially Owned by 8 Shared Voting Power 212,766
----- ----------------------------------------
Each Reporting Person With 9 Sole Dispositive Power -0-
----- ----------------------------------------
10 Shared Dispositive Power 212,766
--------------------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned by Each Reporting Person 212,766
--------------------------------------------------------------------------------
12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions) |_|
--------------------------------------------------------------------------------
13 Percent of Class Represented by Amount in Row (11) 1.46%
--------------------------------------------------------------------------------
14 Type of Reporting Person (See Instructions)
PN
================================================================================
4
---------------------
CUSIP No. 37250B14
---------------------
================================================================================
1 Names of Reporting Persons.
Biomedical Offshore Value Fund, Ltd.
I.R.S. Identification Nos. of above persons (entities only).
N/A
--------------------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3 SEC Use Only
--------------------------------------------------------------------------------
4 Source of Funds (See Instructions) PF
--------------------------------------------------------------------------------
5 Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e) |_|
--------------------------------------------------------------------------------
6 Citizenship or Place of Organization Delaware
--------------------------------------------------------------------------------
Number of Shares 7 Sole Voting Power -0-
----- ----------------------------------------
Beneficially Owned by 8 Shared Voting Power 212,766
----- ----------------------------------------
Each Reporting Person With 9 Sole Dispositive Power -0-
----- ----------------------------------------
10 Shared Dispositive Power 212,766
--------------------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned by Each Reporting Person 212,766
--------------------------------------------------------------------------------
12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions) |_|
--------------------------------------------------------------------------------
13 Percent of Class Represented by Amount in Row (11) 1.46%
--------------------------------------------------------------------------------
14 Type of Reporting Person (See Instructions)
OO
================================================================================
5
This Amendment No. 1 to Schedule 13D (this "Amendment") is filed by
the undersigned to amend the Statement on Schedule 13D, filed by the undersigned
on October 24, 2005 (the "Original Filing"). Unless otherwise indicated, all
capitalized terms shall have the same meaning as provided in the Original
Filing. Any reference to "this Schedule 13D" in the Original Filing or in this
Amendment shall refer to the Original Filing as amended by this Amendment.
ITEM 1. SECURITY AND ISSUER
The title and class of equity securities to which this statement on
Schedule D relates is American Depositary Shares ("ADS"), each representing one
ordinary share of Gentium SpA (the "Issuer"). The ADSs have been issued pursuant
to a Deposit Agreement dated as of June 15, 2005, among the Issuer, the Bank of
New York, as Depositary, and the owners from time to time of ADSs issued
thereunder.
The name and address of the principal executive offices of the Issuer
is Gentium SpA, Piazze XX Septembre 2, 22079 ViVa Guardia, Como Italy.
ITEM 2. IDENTITY AND BACKGROUND
Item 2 is hereby amended to change the address of Biomedical Value
Fund, L.P. ("BMVF"), Great Point Partners LLC ("Great Point"), and Dr. Jeffrey
R. Jay ("Dr. Jay"), from 2 Pickwick Plaza, Suite 450, Greenwich, CT, 06830 (as
originally filed on October 24, 2005), to the current principal office at 165
Mason Street, 3rd Floor, Greenwich, CT, 06830.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
Not applicable.
ITEM 4. PURPOSE OF TRANSACTION
Between June 13th and 15th, 2007, each of BMVF and BOVF sold all of the
ADSs owned by them. See Item 5 for continuing beneficial ownership.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
Item 5 is hereby amended and restated as follows:
(a) through (b)
BMVF owns warrants to purchase 212,766 ADSs. Such securities, in the
aggregate, constitute 1.46% percent of the outstanding share capital of the
Issuer, computed in accordance with Rule 13d-3. BMVF shares dispositive power
over the warrants to purchase ADSs owned by it and, in the event of the exercise
of such warrants, would share voting power with respect to the ADSs for which
such warrants are exerciseable. BMVF disclaims beneficial ownership of any
securities owned by BOVF. See Item 2.
6
BOVF owns warrants to purchase 212,766 ADSs. Such securities, in the
aggregate, constitute 1.46% percent of the outstanding share capital of the
Issuer, computed in accordance with Rule 13d-3. BOVF shares dispositive power
over the warrants to purchase ADSs owned by it and, in the event of the exercise
of such warrants, would share voting power with respect to the ADSs for which
such warrants are exerciseable. BOVF disclaims beneficial ownership of any
securities owned by BMVF. See Item 2.
The warrants to purchase ADSs will be issued only if the issuance
thereof, including the ordinary shares of the Issuer underlying the ADSs, are
authorized at a shareholders' meeting of the Issuer.
Great Point is the investment manager of each of BMVF and BOVF, and by
virtue of such status has shared voting and investment power with respect to
securities owned and held by BMVF and BOVF and may be deemed to be the
beneficial owner of such securities. Dr. Jay, as senior managing member of Great
Point, has shared voting and investment power with respect to securities owned
and held by BMVF and BOVF and may be deemed to be the beneficial owner of such
securities. Great Point and Dr. Jay disclaim beneficial ownership of the shares
of Common stock held by BMVF and BOVF, except to the extent of any pecuniary
interest, and this Schedule 13D shall not be deemed to be an admission that they
are the beneficial owners of such securities.
(c) From the period between June 13, 2007 and June 15, 2007 BMVF sold
531,915 ADSs held by it and BOVF sold 531,915 ADSs held by it.
(d) Not applicable.
(e) Each of the persons referred to in Item 2 ceased to be the
beneficial owner of more than five percent of any class of securities of the
Issuer on June 15, 2007.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO
SECURITIES OF THE ISSUER
Not applicable.
7
ITEM 7. MATERIALS TO BE FILED AS EXHIBITS
EXHIBIT A: Joint Filing Agreement, dated as of October 21, 2005 (as filed on
the Schedule 13D dated as of October 24, 2005, and incorporated
herein by reference).
8
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: June 19, 2007
Biomedical Value Fund, L.P.
By: Great Point GP, LLC, its general
partner
By: /S/ DR. JEFFREY R. JAY
--------------------------------------
Name: Dr. Jeffrey R. Jay
Title: Senior Managing Member
Biomedical Offshore Value Fund, Ltd.
By: Great Point GP, LLC, its investment
manager
By: /S/ DR. JEFFREY R. JAY
--------------------------------------
Name: Dr. Jeffrey R. Jay
Title: Senior Managing Member
Great Point Partners, LLC
By: /S/ DR. JEFFREY R. JAY
--------------------------------------
Name: Dr. Jeffrey R. Jay
Title: Senior Managing Member
/S/ DR. JEFFREY R. JAY
--------------------------------------
Dr. Jeffrey R. Jay, individually